Key Highlights

  • Revenue was USD 37.5 million against a USD 44.21 million estimate, with EPS of USD -2.21 against USD -2.45.
  • An FDA advisory panel voted in favor of approving the Galleri test in September, with a decision targeted early 2027.
  • Galleri Volume rose about 24% to more than 56,000 tests, and Galleri Revenue rose 14% to USD 37.3 million.
  • Cash, cash equivalents and short-term marketable securities totaled USD 788.7 million at September 30, including USD 29.0 million of cash.

The September vote by the FDA's Molecular and Clinical Genetics Panel of the Medical Device Advisory Committee in favor of approval of the Galleri multi-cancer early detection test framed GRAIL, Inc.'s (NASDAQ:GRAL) third quarter. Chief executive Josh Ofman called it a milestone on the path toward potential regulatory approval, broader access and reimbursement. The company targets an FDA decision by early Q1 2027, and the Galleri test remains not cleared or approved by the FDA.

How the Vote Fits the Quarter

The company reported that more than 56,000 Galleri tests were performed in the quarter, up about 24%, and more than 174,000 year to date, up about 36%. Management pointed to promotional pricing initiatives and market education as factors it said were gaining traction. Alongside the vote, the company cited published results from the NHS-Galleri trial and the PATHFINDER 2 study, covering approximately 175,000 participants in the UK and North America. It stated that the studies showed 4 to 6.5 times more cancers detected and, in the NHS-Galleri trial, a reduction of more than 20% in Stage IV diagnoses of 12 prespecified aggressive cancers.

Results Around the Event

Total revenue was USD 37.5 million against USD 36.2 million a year earlier, an increase the company stated as 4%. Screening revenue was USD 37.27 million against USD 32.81 million, while development services revenue was USD 0.27 million against USD 3.39 million. Nine-month Galleri revenue was USD 119.7 million, up 24%.

Costs rose in several lines. Cost of screening revenue was USD 22.03 million against USD 15.91 million, sales and Marketing expense was USD 41.7 million against USD 25.5 million, and general and administrative expense was USD 40.7 million against USD 37.4 million. Research and Development expense was USD 44.1 million against USD 48.6 million. Gross loss was USD 18.1 million against USD 13.7 million, and adjusted Gross Profit was USD 15.9 million against USD 20.0 million.

Loss from operations was USD 144.6 million. After interest income of USD 7.8 million and an income tax benefit of USD 33.8 million, net loss was USD 103.6 million, or USD 2.21 per share, against USD 89.0 million, or USD 2.46. Adjusted EBITDA was negative USD 92.6 million against negative USD 71.7 million.

Cash, Balance Sheet and Timeline

Cash and cash equivalents were USD 29.0 million and short-term marketable securities were USD 759.7 million, totaling USD 788.7 million, against USD 249.7 million and USD 654.7 million at December 31, 2025. Total liabilities were USD 277.0 million and stockholders' Equity was USD 2.45 billion. Shares outstanding were 44,753,179 against 40,331,360. Nine-month net loss was USD 307.0 million, which included a USD 25.4 million Impairment charge recognized in the second quarter.

The company did not provide numerical financial guidance. Its stated timeline centers on the FDA decision, which it targets by early Q1 2027.

Balance Sheet and Cash Markers

Revenue of USD 37.5 million sits alongside a net loss of USD 103.6 million, adjusted EBITDA of negative USD 92.6 million and cash and securities of USD 788.7 million.

Management named a short list of items going forward: the FDA decision targeted by early Q1 2027, regulatory approval, broader access and reimbursement for Galleri, and continued commercial work through education and promotional pricing. Intangible assets stood at USD 1.75 billion on the balance sheet, with USD 33.5 million of quarterly amortization recorded in cost of revenue.